+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of new combinations of treatments, including novel drugs and standard therapies, for patients with advanced or metastatic non-small cell lung cancer NSCLC. This multicenter, open-label study focuses on participants with stage IV NSCLC, specifically assessing combinations involving rilvegostomig with platinum-based chemotherapy and with or without ramucirumab. The study includes a sub-study with safety and dose expansion phases to identify the recommended dose and assess treatment activity. Participants with squamous and non-squamous NSCLC will receive intravenous infusions of rilvegostomig combined with standard chemotherapy drugs such as cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel. Some participants will also receive ramucirumab as part of their treatment. The sub-study consists of a Part A safety run-in to evaluate dose levels and a Part B expansion phase to further study the treatments. Participants are randomized into different treatment arms depending on their cancer histology. During the study, participants will undergo monitoring for adverse events, dose-limiting toxicities, and tumor response over approximately 46 months. Assessments include measuring objective response, duration and time to response, disease control, progression-free survival, overall survival, and various blood drug concentration parameters. Tumor tissue samples are required for evaluation, and safety and tolerability are closely monitored throughout the treatment period.

Age: 18Years +All GendersPhase 1Phase 2
103 locations
S

Actively Recruiting

Atrial fibrillation AF is a major cause of heart-related illness and death, especially among Asian patients who face higher risks of serious bleeding such as brain hemorrhage compared to non-Asians. This research, called the COhort of antithrOmbotic use and cLinical outcomes in patients with Atrial Fibrillation COOL-AF Phase 2, aims to study how antithrombotic medication use changes over time and how these changes affect health outcomes in people with AF. The study is observational and conducted across multiple centers in Thailand. Participants in this study have known or newly diagnosed non-valvular AF and are followed without any intervention or treatment assigned by the study. The study plans to enroll about 3680 patients over two years from 33 centers. Participants will be monitored every 6 months for up to 3 years to observe patterns of medication use, particularly warfarin and non-vitamin K antagonist oral anticoagulants NOACs, and clinical events including stroke, systemic embolism, bleeding, heart attacks, and heart failure. Throughout the study, patients will have regular check-ins every six months to track their medication usage and health status. Researchers will collect data on important outcomes such as rates of stroke, bleeding events, and quality of life. The studys primary focus is on long-term safety and effectiveness of antithrombotic treatments in this population. The total participation duration can be up to 3 years, ensuring thorough observation of clinical outcomes and treatment patterns.

Age: 18Years - 100YearsAll Genders
33 locations
P

Actively Recruiting

Researchers are evaluating the effects of tozorakimab, a drug given by injection under the skin, in adults with uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids. This phase IIb study is designed to find the right dose and assess how safe and effective tozorakimab is for reducing severe asthma attacks over a period of 26 to 52 weeks. Participants will be randomly assigned to receive one of two doses of tozorakimab or a placebo, all given subcutaneously. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The treatment period lasts up to 52 weeks with regular monitoring. The study will measure asthma exacerbation rates, lung function changes, asthma control, quality of life, and drug levels in the blood. During the trial, participants will complete daily asthma diaries to track symptoms and medication use, and attend visits for lung function tests, questionnaires, and blood samples. Safety and antibody responses to the drug will be monitored throughout. Participation lasts up to about one year, including screening and treatment, with regular visits to assess health and response to the study drug.

Age: 18Years - 75YearsAll GendersPhase 2
223 locations